SPARCL1 and neoplasm: The expression of SPARCL1 in pathologic tumor stages 3 and 4, patients were significantly lower than that in pathologic tumor stages 0, 1, and 2, patients on the basis of a comparison of immunoreactivity score (Figure 3B and Supplementary Figure S1A).